Exact Sciences CMS approval expected by early September, says Canaccord Canaccord met with Exact Sciences management and came away confident in the CMS' preliminary reimbursement amount, which the firm expects by early September. Canaccord also noted checks into the company's call center indicated strong interest in Cologuard and it expects targeted digital advertising to raise awareness of its product. The firm raised its price target on the stock to $21 from $20 and keeps its Buy rating on the shares.
Exact Sciences price target lowered to $26 from $32 at Canaccord Canaccord lowered its price target on Exact Sciences to $26 from $32 to reflect dilution of the large secondary offering. The firm maintains its Buy rating on Exact Sciences shares, citing its sales force expansion, payer traction and a high probability of a positive outcome from the USPSTF decision.